JP2005505503A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005505503A5 JP2005505503A5 JP2002587459A JP2002587459A JP2005505503A5 JP 2005505503 A5 JP2005505503 A5 JP 2005505503A5 JP 2002587459 A JP2002587459 A JP 2002587459A JP 2002587459 A JP2002587459 A JP 2002587459A JP 2005505503 A5 JP2005505503 A5 JP 2005505503A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- peptides
- positions
- protein
- hpv16
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 96
- 102000004196 processed proteins & peptides Human genes 0.000 claims 43
- 239000000203 mixture Substances 0.000 claims 25
- 108090000623 proteins and genes Proteins 0.000 claims 23
- 102000004169 proteins and genes Human genes 0.000 claims 19
- 241000341655 Human papillomavirus type 16 Species 0.000 claims 13
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 claims 6
- 102100038823 RNA-binding protein 45 Human genes 0.000 claims 6
- 101000954493 Human papillomavirus type 16 Protein E6 Proteins 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 150000001413 amino acids Chemical group 0.000 claims 4
- 108700028369 Alleles Proteins 0.000 claims 3
- 101000691214 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 50S ribosomal protein L44e Proteins 0.000 claims 3
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 claims 3
- 108010028921 Lipopeptides Proteins 0.000 claims 3
- 230000002163 immunogen Effects 0.000 claims 3
- 108010039343 HLA-DRB1 Chains Proteins 0.000 claims 2
- 230000027455 binding Effects 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 101150034979 DRB3 gene Proteins 0.000 claims 1
- 101150082328 DRB5 gene Proteins 0.000 claims 1
- 238000011510 Elispot assay Methods 0.000 claims 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 claims 1
- 102100040482 HLA class II histocompatibility antigen, DR beta 3 chain Human genes 0.000 claims 1
- 102100028636 HLA class II histocompatibility antigen, DR beta 4 chain Human genes 0.000 claims 1
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 claims 1
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 1
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 1
- 108010061311 HLA-DRB3 Chains Proteins 0.000 claims 1
- 108010040960 HLA-DRB4 Chains Proteins 0.000 claims 1
- 101710154606 Hemagglutinin Proteins 0.000 claims 1
- 101000854908 Homo sapiens WD repeat-containing protein 11 Proteins 0.000 claims 1
- 101100278514 Oryza sativa subsp. japonica DRB2 gene Proteins 0.000 claims 1
- 101100117565 Oryza sativa subsp. japonica DRB4 gene Proteins 0.000 claims 1
- 101100117569 Oryza sativa subsp. japonica DRB6 gene Proteins 0.000 claims 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims 1
- 241000223960 Plasmodium falciparum Species 0.000 claims 1
- 101710176177 Protein A56 Proteins 0.000 claims 1
- 108010090804 Streptavidin Proteins 0.000 claims 1
- 230000006052 T cell proliferation Effects 0.000 claims 1
- 108010055044 Tetanus Toxin Proteins 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 102100020705 WD repeat-containing protein 11 Human genes 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 238000001516 cell proliferation assay Methods 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical group O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 claims 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 239000000185 hemagglutinin Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 229940118376 tetanus toxin Drugs 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0105980A FR2824326B1 (fr) | 2001-05-04 | 2001-05-04 | Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications |
| PCT/FR2002/001533 WO2002090382A2 (fr) | 2001-05-04 | 2002-05-03 | Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005505503A JP2005505503A (ja) | 2005-02-24 |
| JP2005505503A5 true JP2005505503A5 (enExample) | 2005-12-22 |
Family
ID=8862980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002587459A Withdrawn JP2005505503A (ja) | 2001-05-04 | 2002-05-03 | Ｅ６及び／又はｅ７パピローマウイルスタンパク質に由来するペプチドの混合物並びにその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7488791B2 (enExample) |
| EP (1) | EP1383535A2 (enExample) |
| JP (1) | JP2005505503A (enExample) |
| AU (1) | AU2002302713A1 (enExample) |
| CA (1) | CA2446062A1 (enExample) |
| FR (1) | FR2824326B1 (enExample) |
| WO (1) | WO2002090382A2 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL105554A (en) * | 1992-05-05 | 1999-08-17 | Univ Leiden | Peptides of human papillomavirus for use in preparations elicit a human T cell response |
| US20050100928A1 (en) * | 1999-09-16 | 2005-05-12 | Zycos Inc., A Delaware Corporation | Nucleic acids encoding polyepitope polypeptides |
| DE10336916B4 (de) * | 2003-08-07 | 2015-02-19 | Danfoss A/S | Regelventil und Wärmetauscheranordnung |
| US7576323B2 (en) * | 2004-09-27 | 2009-08-18 | Johns Hopkins University | Point-of-care mass spectrometer system |
| JP2008044848A (ja) * | 2004-11-30 | 2008-02-28 | Univ Kurume | Ｈｌａ−ａ２４拘束性腫瘍抗原ペプチド |
| US7972776B2 (en) * | 2005-11-15 | 2011-07-05 | Oncohealth Corporation | Protein chips for HPV detection |
| ES2310072B1 (es) * | 2005-12-23 | 2009-11-16 | Proyecto De Biomedicina Cima, S.L. | Nuevos peptidos determinantes antigenicos t colaboradores (/dth). |
| US8968995B2 (en) * | 2008-11-12 | 2015-03-03 | Oncohealth Corp. | Detection, screening, and diagnosis of HPV-associated cancers |
| US20100003704A1 (en) * | 2008-06-13 | 2010-01-07 | Shuling Cheng | IN SITU detection of early stages and late stages HPV infection |
| US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
| AU2008257792B2 (en) | 2007-05-31 | 2013-08-29 | Isa Pharmaceuticals B.V. | HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines |
| AU2013205259B2 (en) * | 2007-05-31 | 2015-06-11 | Isa Pharmaceuticals B.V. | HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines |
| KR20090103571A (ko) * | 2008-03-28 | 2009-10-01 | 바이오코아 주식회사 | 면역성 펩타이드 및 그 펩타이드를 포함하는 ｈｐｖ 관련질환 예방 또는 치료용 조성물 |
| BRPI0910464B1 (pt) | 2008-04-17 | 2021-08-10 | Pds Biotechnology Corporation | Uso de uso de um lipídio catiônico quiral consistindo de r-dotap a preparação de composição farmacêutica |
| EP2427763A4 (en) | 2009-05-07 | 2013-08-21 | Oncohealth Corp | IDENTIFICATION OF A HIGH CIN2 DEGREE FOR THE DETECTION OF EARLY AND LATE TADIES AND FOR THE SCREENING AND DIAGNOSIS OF HUMAN PAPILLOMA (HPV) AND ASSOCIATED CANCER DISORDERS |
| AR074485A1 (es) * | 2009-12-04 | 2011-01-19 | Consejo Nac Invest Cient Tec | Vacuna contra lesiones neoplasicas o cancerosas causadas por el virus del papiloma humano (vph), procedimientos, usos y metodos |
| CN102822672B (zh) | 2010-01-08 | 2015-12-09 | 安科健康公司 | 用于诊断和筛选与hpv有关的癌症的高通量细胞基hpv免疫测定 |
| CN102060929A (zh) * | 2010-06-07 | 2011-05-18 | 夏书奇 | T细胞免疫平衡肽 |
| CA2819416C (en) | 2010-12-02 | 2019-04-30 | Bionor Immuno As | Peptide scaffold design |
| US9931359B2 (en) | 2012-05-08 | 2018-04-03 | The Johns Hopkins University | Methods and compositions for infusion of transiently engrafting, selected populations of allogeneic lymphocytes to treat cancer |
| AU2013274235B2 (en) | 2012-06-15 | 2018-01-18 | Samir N. Khleif | Cationic lipid vaccine compositions and methods of use |
| WO2014047533A1 (en) | 2012-09-21 | 2014-03-27 | Frank Bedu-Addo | Improved vaccine compositions and methods of use |
| FR3008099B1 (fr) | 2013-07-05 | 2020-08-07 | Commissariat Energie Atomique | Peptides immunogenes de l'antigene tumoral cycline b1 |
| EP3058956A1 (en) | 2015-02-23 | 2016-08-24 | Institut Curie | Combined vaccination/radioterapy for cancer treatment |
| CA3005251A1 (en) | 2015-11-13 | 2017-05-18 | Pds Biotechnology Corporation | Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy |
| MY201964A (en) | 2016-06-20 | 2024-03-27 | Isa Pharmaceuticals B V | Formulation of a peptide vaccine |
| EP3267119A1 (en) | 2016-07-07 | 2018-01-10 | E.ON Sverige AB | Combined heating and cooling system |
| KR20190073416A (ko) * | 2016-10-05 | 2019-06-26 | 피디에스 바이오테크놀러지 코퍼레이션 | 신규한 hpv16 hla-비제한적 t-세포 백신, 조성물 및 이의 사용 방법 |
| AU2019213286A1 (en) * | 2018-01-24 | 2020-07-30 | The Council Of The Queensland Institute Of Medical Research | HPV immunotherapy |
| WO2019210055A2 (en) * | 2018-04-26 | 2019-10-31 | Agenus Inc. | Heat shock protein-binding peptide compositions and methods of use thereof |
| JP7688576B6 (ja) * | 2018-11-28 | 2025-07-04 | ザ ジェネラル ホスピタル コーポレイション | 共生ウイルスに対するｔ細胞指向性抗がんワクチン |
| US20230100653A1 (en) * | 2020-02-10 | 2023-03-30 | The Johns Hopkins University | Cancer immunotherapy using transfusions of allogeneic, tumor-specific cd4+ t cells |
| EP4281106A4 (en) * | 2021-01-21 | 2024-12-25 | The General Hospital Corporation | T-CELL-TARGETED ANTICANCER VACCINES AGAINST COMMENSAL VIRUSES FOR THE TREATMENT OF MUCOSAIC CARCINOMAS |
| WO2024223299A2 (en) | 2023-04-26 | 2024-10-31 | Isa Pharmaceuticals B.V. | Methods of treating cancer by administering immunogenic compositions and a pd-1 inhibitor |
| CN119569831A (zh) * | 2024-12-13 | 2025-03-07 | 深圳锦时生物科技有限公司 | 一种活性多肽及在预防和/或治疗hpv中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9001705D0 (sv) * | 1990-05-11 | 1990-05-11 | Medscand Ab | Saett foer diagnostik av virusbaerande tumoerer genom immunoassay |
| US5932412A (en) * | 1990-05-11 | 1999-08-03 | Euro-Diagnostica Ab | Synthetic peptides in human papillomaviruses 1, 5, 6, 8, 11, 16, 18, 31, 33 and 56, useful in immunoassay for diagnostic purposes |
| DK0523391T3 (da) * | 1991-07-13 | 2003-06-23 | Dade Behring Marburg Gmbh | Anvendelse af HPV-16 E6 og E7 genafledte peptider til diagnostisk formål |
| CO4600681A1 (es) * | 1996-02-24 | 1998-05-08 | Boehringer Ingelheim Pharma | Composicion farmaceutica para la modulacion inmunitaria |
| WO1999034826A1 (en) * | 1998-01-09 | 1999-07-15 | Circassia Limited | Methods and compositions for desensitisation |
| FR2794370B1 (fr) * | 1999-06-03 | 2003-10-17 | Biovector Therapeutics | Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination |
| CA2377525A1 (en) * | 1999-07-19 | 2001-03-29 | Epimmune, Inc. | Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions |
| SE9903031D0 (sv) * | 1999-08-27 | 1999-08-27 | Eurodiagnostica Ab | Peptide mixture and vaccine against a chronic viral infection |
| DE60042556D1 (de) * | 1999-09-16 | 2011-02-10 | Eisai Inc | Für polyepitop-polypeptide kodierende nukleinsäuren |
| US20050100928A1 (en) * | 1999-09-16 | 2005-05-12 | Zycos Inc., A Delaware Corporation | Nucleic acids encoding polyepitope polypeptides |
| WO2001024810A1 (en) * | 1999-10-05 | 2001-04-12 | Epimmune Inc. | Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions |
-
2001
- 2001-05-04 FR FR0105980A patent/FR2824326B1/fr not_active Expired - Fee Related
-
2002
- 2002-05-03 CA CA 2446062 patent/CA2446062A1/fr not_active Abandoned
- 2002-05-03 WO PCT/FR2002/001533 patent/WO2002090382A2/fr not_active Ceased
- 2002-05-03 EP EP02730391A patent/EP1383535A2/fr not_active Withdrawn
- 2002-05-03 JP JP2002587459A patent/JP2005505503A/ja not_active Withdrawn
- 2002-05-03 AU AU2002302713A patent/AU2002302713A1/en not_active Abandoned
- 2002-05-03 US US10/476,570 patent/US7488791B2/en not_active Expired - Fee Related
-
2008
- 2008-12-31 US US12/347,471 patent/US20100203080A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005505503A5 (enExample) | ||
| US7488791B2 (en) | Mixture of peptides derived from E6 and/or E7 papillomavirus proteins and uses thereof | |
| Ressing et al. | Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A* 0201-binding peptides. | |
| JP2768928B2 (ja) | ウシ乳頭腫ウィルスのｄｎａ断片 | |
| CA2692652C (en) | Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines | |
| Steven et al. | Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus–induced cytotoxic T cell response | |
| US6413517B1 (en) | Identification of broadly reactive DR restricted epitopes | |
| US8252893B2 (en) | CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof | |
| Majewski et al. | Antibodies to human papillomavirus type 5 are generated in epidermal repair processes | |
| CA2821995C (en) | Monomeric and multimeric peptides immunogenic against hiv | |
| US7468186B2 (en) | Polyomavirus cellular epitopes and uses therefor | |
| Bourgault et al. | Simian immunodeficiency virus as a model for vaccination against HIV. Induction in rhesus macaques of GAG-or NEF-specific cytotoxic T lymphocytes by lipopeptides. | |
| US11179456B2 (en) | HPV vaccine | |
| US20190125856A1 (en) | Improvement of L2 Peptide Immunogenicity | |
| Lewicki et al. | CTL escape viral variants: II. Biologic activity in vivo | |
| Ressing et al. | Differential binding of viral peptides to HLA‐A2 alleles. Implications for human papillomavirus type 16 E7 peptide‐based vaccination against cervical carcinoma | |
| Ohno et al. | Synthetic peptides coupled to the surface of liposomes effectively induce SARS coronavirus-specific cytotoxic T lymphocytes and viral clearance in HLA-A* 0201 transgenic mice | |
| JP2008529486A5 (enExample) | ||
| Akbari et al. | In silico design and in vitro expression of novel multiepitope DNA constructs based on HIV-1 proteins and Hsp70 T-cell epitopes | |
| Vasilakos et al. | Herpes simplex virus class I-restricted peptide induces cytotoxic T lymphocytes in vivo independent of CD4+ T cells | |
| Simons et al. | Characterization of poliovirus-specific T lymphocytes in the peripheral blood of Sabin-vaccinated humans | |
| Liu et al. | The high prevalence of the I27 mutant HBcAg18–27 epitope in Chinese HBV-infected patients and its cross-reactivity with the V27 prototype epitope | |
| AU2022208375A9 (en) | Cytolytic t cell immunotherapy for highly pathogenic coronaviruses | |
| Serangeli et al. | Ex vivo detection of adenovirus specific CD4+ T-cell responses to HLA-DR-epitopes of the Hexon protein show a contracted specificity of THELPER cells following stem cell transplantation | |
| Schell et al. | Cytotoxic T lymphocytes from HLA-A2. 1 transgenic mice define a potential human epitope from simian virus 40 large T antigen |